Lenire Biosciences

Lenire Biosciences operates as a privately-owned, clinical phase biopharmaceutical firm focused on creating innovative, patented treatments for Fragile X Syndrome (FXS), a prominent contributor to cognitive impairment globally, accompanied by anxiety, inattention, hyperactivity, autism spectrum traits, and other incapacitating manifestations.